Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2012 by Jiangsu HengRui Medicine Co., Ltd..
Recruitment status was  Recruiting
Fudan University
NanJing PLA 81 Hospital
Information provided by (Responsible Party):
Jiangsu HengRui Medicine Co., Ltd. Identifier:
First received: January 13, 2012
Last updated: January 24, 2012
Last verified: January 2012

Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor receptor (VEGFR), and it's anti-angiogenesis effect has been viewed in preclinical tests. The investigators' phase I study has shown that the drug's toxicity is manageable and the maximum tolerable daily dose is 850 mg. The purpose of this study is to determine whether apatinib can improve progression free survival or overall survival compared with placebo in patients with metastatic gastric carcinoma who failed two lines of chemotherapy.

Condition Intervention Phase
Advanced or Metastatic Gastric Cancer
Drug: apatinib
Drug: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double Blinded, Placebo Controlled Multicenter Phase III Study of Apatinib Mesylate Tablets in the Treatment of Advanced or Metastatic Gastric Cancer

Resource links provided by NLM:

Further study details as provided by Jiangsu HengRui Medicine Co., Ltd.:

Primary Outcome Measures:
  • PFS [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
    Progression free survival

  • OS [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
    Overall Survival

Secondary Outcome Measures:
  • DCR [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    Disease control rate

  • ORR [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    objective response rate

  • QoL [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
    quality of life

  • Toxicity [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 270
Study Start Date: January 2011
Estimated Study Completion Date: June 2012
Estimated Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: apatinib Drug: apatinib
apatinib 850 mg qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent
Placebo Comparator: placebo Drug: placebo
placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent


Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ≥ 18 and ≤ 70 years of age
  • Histological confirmed advanced or metastatic adenocarcinoma of the stomach
  • Have failed for 2 lines of chemotherapy
  • Life expectancy of more than 3 months
  • ECOG performance scale ≤ 1
  • At least one measurable lesion beyond stomach (larger than 10 mm in diameter by spiral CT scan)
  • Duration from the last therapy is more than 6 weeks for nitroso or mitomycin
  • More than 4 weeks for operation or radiotherapy
  • More than 4 weeks for cytotoxic agents or growth inhibitors
  • Adequate hepatic, renal, heart, and hematologic functions (platelets > 80 × 109/L, neutrophil > 1.5 × 109/L, serum creatinine ≤ 1X upper limit of normal(ULN), bilirubin < 1.25 ULN, and serum transaminase ≤ 2.5× ULN).

Exclusion Criteria:

  • Pregnant or lactating women
  • History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix
  • Any factors that influence the usage of oral administration; Evidence of CNS metastasis
  • Intercurrence with one of the following: uncontrolled hypertension, coronary artery disease, arrhythmia and heart failure
  • INR > 1.5 and APPT > 1.5 X ULN
  • Abuse of alcohol or drugs
  • Certain possibility of gastric or intestine hemorrhage
  • Less than 4 weeks from the last clinical trial
  • Prior VEGFR inhibitor treatment
  • Disability of serious uncontrolled intercurrence infection.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01512745

Contact: jin Li, MD, PHD +86-21-64175590

China, Jiangsu
Millitary Eighty-one Hosiptal Recruiting
Nanjing, Jiangsu, China
Contact: Shukui Qin, MD   
China, Shanghai
Fudan University cancer hospital Recruiting
Shanghai, Shanghai, China
Contact: jin Li, MD, PHd   
Principal Investigator: jin Li, MD, PHD         
Sponsors and Collaborators
Jiangsu HengRui Medicine Co., Ltd.
Fudan University
NanJing PLA 81 Hospital
Principal Investigator: jin Li, MD, PHD Fudan University
Principal Investigator: Shukui Qin, MD Nanjin Military Eighty -one Hosiptal
  More Information

No publications provided

Responsible Party: Jiangsu HengRui Medicine Co., Ltd. Identifier: NCT01512745     History of Changes
Other Study ID Numbers: HENGRUI 20101208
Study First Received: January 13, 2012
Last Updated: January 24, 2012
Health Authority: China: Food and Drug Administration

Additional relevant MeSH terms:
Stomach Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Neoplasms by Site
Stomach Diseases processed this record on March 03, 2015